Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 21 years of age or older
- People who are able to follow simple instructions during eye imaging (similar to what a standard eye exam involves)
- People who are able to understand and sign a consent form (note: the trial does not enrol people whose primary language is not English)
- People who have been diagnosed with a disease or condition affecting the outer part of the retina (the back of the eye)
Who may not be able to join:
- People who have a condition that prevents clear eye images from being taken, such as difficulty keeping the eye still or cloudiness in the eye (confirm with trial site)
- People whose vision prescription falls outside the range of +4 to -8 diopters (a measure of lens strength used in glasses or contact lenses)
- People who have had a bad reaction to eye drops used to widen the pupil (mydriatic drops)
- People who have a tendency toward, or any history of, a sudden type of glaucoma called acute angle closure glaucoma, or who have a narrow drainage angle in the eye that may increase that risk
- People who work directly under the supervision of the named study investigators (Drs. Hammer, Cukras, and Liu) or any of the NIH/NEI research team members listed on the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel X Hammer, Ph.D., Food and Drug Administration (FDA)
Phone: 301-796-9320
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Photoreceptor (PR) density; Retinal pigment epithelial (RPE) cell density; RPE cell organelle motility; PR cell function
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.